Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Enzychem Lifesciences Corp (183490)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,880 +13    +0.70%
26/04 - Closed. Currency in KRW ( Disclaimer )
Type:  Equity
Market:  South Korea
ISIN:  KR7183490002 
  • Volume: 237,211
  • Bid/Ask: 1,879 / 1,880
  • Day's Range: 1,852 - 1,883
Enzychem Lifesciences 1,880 +13 +0.70%

183490 Balance Sheet

 
Featured here, the Balance Sheet for Enzychem Lifesciences Corp, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 174475.03 179355.52 177567.61 184240.67
Cash and Short Term Investments 137350.22 145356.43 151687.09 159838.06
Cash - - - -
Cash & Equivalents 15470.22 4672.84 8102.84 3371.96
Short Term Investments 121604 125598.12 143584.25 156466.1
Total Receivables, Net 20207.42 17425.41 10565.9 8631.47
Accounts Receivables - Trade, Net 11625.32 13022.77 8486.14 6129.17
Total Inventory 14945.87 14401.14 13771.19 12616.84
Prepaid Expenses 134.77 173.27 149.94 122.29
Other Current Assets, Total 1836.75 1999.26 1393.5 3032.02
Total Assets 211545.51 216222.31 214371.85 219993.76
Property/Plant/Equipment, Total - Net 26164.19 26190.05 26017.79 25298.97
Property/Plant/Equipment, Total - Gross 41363.02 41055.2 40214.06 39041.06
Accumulated Depreciation, Total -15198.83 -14865.15 -14196.28 -13742.09
Goodwill, Net 1479.5 1394.5 1394.5 4330.41
Intangibles, Net 4371.45 4571.58 4723.58 2247.93
Long Term Investments 1573.97 870.23 814.41 820.32
Note Receivable - Long Term 1425.35 860.3 1171.39 1491.62
Other Long Term Assets, Total 2859.43 3398.28 3405.54 2986.67
Other Assets, Total 126233.88 143643.06 149539.83 164562.94
Total Current Liabilities 14154.1 15330.42 11067.43 16280.27
Accounts Payable 6493.2 6998.48 2940.54 3371.17
Payable/Accrued - - - -
Accrued Expenses 10.21 39.25 40.13 43.56
Notes Payable/Short Term Debt 2280 2553.82 2000 2450
Current Port. of LT Debt/Capital Leases 1767.51 1865.47 2602.48 6187.84
Other Current liabilities, Total 3603.18 3873.41 3484.28 4227.71
Total Liabilities 16918.87 20801.47 16214.28 19895.36
Total Long Term Debt 1609.45 1674.4 1579.57 882.65
Long Term Debt 1025 1032.5 1040 389.16
Capital Lease Obligations 584.45 641.9 539.57 493.49
Deferred Income Tax 715.09 735.28 753.03 -
Minority Interest 1110.71 1092.82 1202.16 687.22
Other Liabilities, Total -2950.48 -585.28 -387.89 -404.79
Total Equity 194626.64 195420.84 198157.57 200098.41
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 42532.78 42532.78 42532.78 42532.78
Additional Paid-In Capital 108431.48 108431.48 108431.48 108431.48
Retained Earnings (Accumulated Deficit) 41910.07 42705.15 45339.73 47794.15
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 1752.3 1751.42 1853.57 1339.99
Total Liabilities & Shareholders' Equity 211545.51 216222.31 214371.85 219993.76
Total Common Shares Outstanding 85.07 85.07 85.07 85.07
Total Preferred Shares Outstanding - - - -
* In Millions of KRW (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

183490 Comments

Write your thoughts about Enzychem Lifesciences Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email